Do you want to read an article? Please log in or register.
AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes
Macular Diseases
Related content
Macular Diseases
Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial
JAMA Ophthalmol.
Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, Melia M, Wells JA 3rd; Diabetic Retinopathy Clinical Research Network
doi: 10.1001/
Macular Diseases
Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success
Graefes Arch Clin Exp Ophthalmol.
Laiginhas R, Silva MI, Rosas V, Penas S, Fernandes VA, Rocha-Sousa A, Carneiro Â, Falcão-Reis F, Falcão MS
doi: 10.1007/s00417-017-3836-1.
RECOMMENDED
Macular Diseases
Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry
★ 3
Recommended by
Prof. Dr Daniel Barthelmes, Faculty Member
★ 3
Recommended by
Prof. Dr Ke Yao, Faculty Member
Ophthalmology.
Bhandari S, Nguyen V, Fraser-Bell S, Mehta H, Viola F, Baudin F, Gabrielle PH, Creuzot-Garcher C, Gillies M, Barthelmes D
doi: 10.1016/j.ophtha.2019.11.018.
COMMENTED
Macular Diseases
Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study)
doi: 10.1016/j.ophtha.2020.03.021.
Macular Diseases
Longitudinal Retinal Perfusion Status in Eyes with Diabetic Macular Edema Receiving Intravitreal Aflibercept or Laser in VISTA study
Ophthalmology.
Wykoff CC, Shah C, Dhoot D, Coleman HR, Thompson D, Du W, Baker K, Vitti R, Berliner AJ, Metzig C, Saroj N
doi: 10.1016/j.ophtha.
COMMENTED
Macular Diseases
Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial
JAMA Ophthalmol.
Bressler NM, Odia I, Maguire M, Glassman AR, Jampol LM, MacCumber MW, Shah C, Rosberger D, Sun JK, DRCR Retina Network.
doi: 10.1001/jamaophthalmol.
Macular Diseases
Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema
Sci Rep
Hirano T, Toriyama Y, Takamura Y, Sugimoto M, Nagaoka T, Sugiura Y, Okamoto F, Saito M, Noda K, Yoshida S, Ishibazawa A, Sawada O, Murata T
doi: 10.1038/s41598-021-83811-y
Macular Diseases
Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study
Ophthalmol Retina.
Garweg JG, Stefanickova J, Hoyng C, Schmelter T, Niesen T, Sowade O, Sivaprasad S, AQUA Investigators.
doi: 10.1016/j.oret.2019.03.012.
COMMENTED
Macular Diseases
Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial
JAMA.
Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, Chalam KV, Grover S, Jampol LM, Jhaveri CD, Melia M, Stockdale CR, Martin DF, Sun JK, DRCR Retina Network.
doi: 10.1001/jama.2019.5790.